FDA advisory panel votes to recommend six unproven peptides, sparking safety debate

Published Aug 3, 07:06 PM UTC

An FDA advisory panel voted to recommend adding six unproven peptides to the list of drugs that compounding pharmacies can sell, despite safety and efficacy concerns. The vote was influenced by Health Secretary Robert F. Kennedy Jr., who added eight new members to the panel, six of whom run clinics offering these peptides. Proponents argue that thousands already use potentially dangerous black market peptides and that regulated access would be safer. Critics, including FDA scientists, cite a lack of clinical trial data and risk of harmful immune reactions. The decision is seen as part of a broader push to bypass strict FDA evidence standards, driven by demand from wellness influencers and celebrities. Experts warn this could open a 'Pandora's box' of untested drugs, undermining the FDA's role as a consumer protection agency.